Literature DB >> 17447431

Iron dyshomeostasis in Parkinson's disease.

J Salazar1, N Mena, M T Núñez.   

Abstract

Owing to its ability to undergo one-electron reactions, iron transforms the mild oxidant hydrogen peroxide into hydroxyl radical, one of the most reactive species in nature. Deleterious effects of iron accumulation are dramatically evidenced in several neurodegenerative diseases. The work of Youdim and collaborators has been fundamental in describing the accumulation of iron confined to the substantia nigra (SN) in Parkinson's disease (PD) and to clarify iron toxicity pathways and oxidative damage in dopaminergic neurons. Nevertheless, how the mechanisms involved in normal neuronal iron homeostasis are surpassed, remain largely undetermined. How nigral neurons survive or succumb to iron-induced oxidative stress are relevant questions both to know about the etiology of the disease and to design neuroprotective strategies. In this work, we review the components of neural iron homeostasis and we summarize evidence from recent studies aimed to unravel the molecular basis of iron accumulation and dyshomeostasis in PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17447431     DOI: 10.1007/978-3-211-33328-0_22

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  8 in total

Review 1.  Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.

Authors:  Isidre Ferrer; Anna Martinez; Rosa Blanco; Ester Dalfó; Margarita Carmona
Journal:  J Neural Transm (Vienna)       Date:  2010-09-23       Impact factor: 3.575

2.  Increased hippocampal expression of the divalent metal transporter 1 (DMT1) mRNA variants 1B and +IRE and DMT1 protein after NMDA-receptor stimulation or spatial memory training.

Authors:  Paola Haeger; Alvaro Alvarez; Nancy Leal; Tatiana Adasme; Marco Tulio Núñez; Cecilia Hidalgo
Journal:  Neurotox Res       Date:  2009-08-05       Impact factor: 3.911

3.  Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease.

Authors:  Julio Salazar; Natalia Mena; Stephane Hunot; Annick Prigent; Daniel Alvarez-Fischer; Miguel Arredondo; Charles Duyckaerts; Veronique Sazdovitch; Lin Zhao; Laura M Garrick; Marco T Nuñez; Michael D Garrick; Rita Raisman-Vozari; Etienne C Hirsch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

4.  Brain iron dysregulation and the risk of ageing white matter lesions.

Authors:  Ola H Gebril; J E Simpson; Janine Kirby; Carol Brayne; Paul G Ince
Journal:  Neuromolecular Med       Date:  2011-10-07       Impact factor: 3.843

Review 5.  Nutraceuticals against Neurodegeneration: A Mechanistic Insight.

Authors:  Vivekkumar P Dadhania; Priyanka P Trivedi; Ajit Vikram; Durga Nand Tripathi
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 6.  Parkinson's Disease: The Mitochondria-Iron Link.

Authors:  Yorka Muñoz; Carlos M Carrasco; Joaquín D Campos; Pabla Aguirre; Marco T Núñez
Journal:  Parkinsons Dis       Date:  2016-05-17

Review 7.  New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases.

Authors:  Marco T Nuñez; Pedro Chana-Cuevas
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-19

8.  Systematic Surveys of Iron Homeostasis Mechanisms Reveal Ferritin Superfamily and Nucleotide Surveillance Regulation to be Modified by PINK1 Absence.

Authors:  Jana Key; Nesli Ece Sen; Aleksandar Arsović; Stella Krämer; Robert Hülse; Natasha Nadeem Khan; David Meierhofer; Suzana Gispert; Gabriele Koepf; Georg Auburger
Journal:  Cells       Date:  2020-10-02       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.